Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012, with the report dated January 10, 2012. The filing serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation plan transactions.
- Share Price: $46.24 per Ordinary share ADR (used for dividend reinvestment).
- Transaction Type: Increase in notional interests in Ordinary share ADRs following dividend reinvestment.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific increases in notional ADR holdings for two individuals:
- Mrs. D P Connelly: Acquired 9.310 ADRs (personal contribution) and 9.574 ADRs (company matching contribution).
- Mr. W C Louv: Acquired 24.623 ADRs (personal contribution) and 25.138 ADRs (company matching contribution).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out based on the percentage of deferred annual bonus holdings that vest after the relevant three-year measurement period.
Key Facts for Investor Verification
- Verify the vesting schedule and conditions for the 2009 Deferred Annual Bonus Plan.
- Confirm the total number of ADRs held by Mrs. D P Connelly and Mr. W C Louv post-transaction.
- Review the dividend payment date of January 5, 2012, to understand the basis for the reinvestment.